Categories: AlternativeDataDevelopmentFinTechHealthTechLegalTechMedTechPlatformPropertyRobotics
KaNDy Therapeutics is a UK based clinical-stage company focused on optimizing the potential of NT-814 as a breakthrough medicine for the treatment of chronic debilitating Women’s Health. NT-814 is a first-in-class, once daily, dual mechanism neurokinin-1,3 receptor antagonist. The medicine is being developed as a non-hormonal alternative to hormone replacement therapy for the treatment of postmenopausal symptoms (PMS). NT-814 has been spun out of NeRRe Therapeutics Holdings Ltd into KaNDy Therapeutics Ltd a separate legal entity. The new company will advance the development of NT-814 into Phase 2b in the lead indication PMS while also exploring its potential in other Women's Health conditions. All formulation, pre-clinical and clinical safety and efficacy data, and intellectual property associated with NT-814 have been transferred to the new company.
Investors 4
Funding Rounds 1
| Date | Series | Amount | Investors |
| 29.08.2018 | Series C | $32.59M | - |
Mentions in press and media 7
| Date | Title | Description | Source |
| 06.03.2020 | Что такое FemTech: полный обзор экосистемы стартапов для жен... | Все говорят про FinTech, EduTech, AgroTech, но на vc.ru не нашлось ни одного упоминания об одном из ... | vc.ru/serv... |
| 30.08.2018 | Term Sheet — Thursday, August 30 | 5 Qs WITH A DEALMAKER
Venture capitalist Ashmeet Sidana believes that some of the best Silicon Vall... | fortune.co... |
| 29.08.2018 | KaNDy Therapeutics successfully raises £25 million in a Seri... | Stevenage, UK, 29 August 2018 - KaNDy Therapeutics, a clinical-stage Women’s Health company, today a... | forbion.co... |
| 29.08.2018 | UK-based KaNDy Therapeutics raises $32.5 million Series C ro... | The company plans to use the money to fund a multinational Phase IIb dose-ranging clinical trial of ... | medcitynew... |
| 29.08.2018 | KaNDy Therapeutics Raises £25M in Series C Financing | KaNDy Therapeutics, a Stevenage, England, UK-based clinical-stage Women’s Health company, closed a £... | finsmes.co... |
| 27.09.2017 | NeRRe splits in two, carving out women’s health company | U.K. biotech NeRRe Therapeutics has decided to streamline its R&D portfolio by setting up a bran... | fiercebiot... |
| - | UK-based KaNDy Therapeutics raises $32.5 million Series C ro... | A British firm developing non-hormonal treatment for symptoms of menopause has raised £25 million ($... | medcitynew... |
Reviews 0
